Skip to content
Subscriber Only

Merck Rises on Outlook for Billions in Covid Antiviral Sales

  • Opportunity for as much as $7 billion through 2022, CFO says
  • Merck has applied for U.S. clearance of Covid antiviral
Updated on

Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker. 

The figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.